Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30663731 | 0.84 | MAPT (0.56) | MAPTMAOBTSHRCA2HPGD | |
| SCHEMBL10347560 | 0.84 | MAPT (0.56) | MAPTMAOBTSHRCA2HPGD | |
| Hydrochloric Acid SCHEMBL21694039 | 0.82 | MAPT (0.55) | MAPTMAOBTSHRCA2HPGD | |
| SCHEMBL20530571 | 0.81 | CYP3A4 (0.49) | MAPTGAAJAK2MAOBCYP3A4 | |
| SCHEMBL20530587 | 0.80 | MAOB (0.42) | MAPTGAAJAK2LMNAMAOB | |
| SCHEMBL18335399 | 0.80 | CYP3A4 (0.41) | MAPTGAAJAK2LMNAMAOB | |
| SCHEMBL10808553 | 0.79 | GAA (0.57) | MAPTGAAJAK2LMNAAPP | |
| SCHEMBL11873912 | 0.79 | GAA (0.57) | MAPTGAAJAK2LMNAAPP | |
| SCHEMBL9855809 | 0.79 | GAA (0.62) | MAPTGAAJAK2LMNAAPP | |
| SCHEMBL26013294 | 0.78 | MAOB (0.64) | MAPTMAOBCA2CYP3A4CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1200431-B3 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTORS LIGANDS | ALMIRALL SA (ES) | 2015-06-24 | — | — | EP | claimed |
| EP-1471919-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIOATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | GLAXO GROUP LTD (GB) | 2005-08-10 | — | — | EP | claimed |
| EP-1200431-B1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTORS LIGANDS | ALMIRALL PRODESFARMA AG (CH) | 2003-03-26 | — | — | EP | claimed |
| US-5367043-A | Durable formaldehyde-free phenolic resins, and method of preparing such resins | ENZYMOL INTERNATIONAL, INC. (US) | 1994-11-22 | — | — | US | claimed |
| CN-114349817-B | Tubulin degrading agent based on VHL ligand and application thereof | 杭州医学院 | 2025-02-11 | — | — | CN | disclosed |
| CN-114349657-B | Azo microtubulin inhibitor and preparation method and application thereof | 杭州医学院 | 2023-12-22 | — | — | CN | disclosed |
| CN-114349657-A | Azo tubulin inhibitor and preparation method and application thereof | 杭州医学院 | 2022-04-15 | — | — | CN | disclosed |
| CN-114349817-A | VHL ligand-based tubulin degrading agent and application thereof | 杭州医学院 | 2022-04-15 | — | — | CN | disclosed |
| CN-114349739-A | Azo compound for degrading tubulin and synthesis method and application thereof | 杭州医学院 | 2022-04-15 | — | — | CN | disclosed |
| US-11117873-B2 | Oxazine compound, composition, and cured product | DIC CORPORATION (JP) | 2021-09-14 | — | — | US | disclosed |
| US-11117872-B2 | Oxazine compound, composition and cured product | DIC CORPORATION (JP) | 2021-09-14 | — | — | US | disclosed |
| US-11028059-B2 | Oxazine compound, composition and cured product | DIC CORPORATION (JP) | 2021-06-08 | — | — | US | disclosed |
| US-20020053302-A1 | Epoxy resin composition for encapsulating semiconductor, and resin-encapsulated type semiconductor apparatus | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-05-09 | — | — | US | disclosed |
| EP-1174455-A1 | Epoxy resin composition for encapsulating semiconductor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1032559-A1 | AMINOALKYLPHENOL DERIVATIVES AND RELATED COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999016746-A1 | AMINOALKYLPHENOL DERIVATIVES AND RELATED COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 1999-04-08 | — | — | WO | disclosed |
| US-4595769-A | Carbamate-sulfenyl-carbamoyl fluoride compounds | UNION CARBIDE CORPORATION (US) | 1986-06-17 | — | — | US | disclosed |
| US-4166864-A | MITICIDES, INSECTICIDES | UNION CARBIDE CORPORATION (US) | 1979-09-04 | — | — | US | disclosed |
| US-4129601-A | BIS ETHERS, PESTICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1978-12-12 | — | — | US | disclosed |
| US-4039685-A | 1-PHENOXY-2-HYDROXY-3-TERT.-BUTYLAMINO PROPANE ANTIARRHYTHMIC COMPOUNDS | BOEHRINGER INGELHEIM GMBH (DT) | 1977-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028059-B2 | Oxazine compound, composition and cured product | KDM5A, WDR5, RNF5 | MAPT 147/4885GAA 2973/4885JAK2 2815/4885 |
| US-20020053302-A1 | Epoxy resin composition for encapsulating semiconductor, and resin-encapsulated type semiconductor apparatus | SEM1, ABCC1, RER1 | MAPT 3895/4885GAA 1666/4885JAK2 1320/4885 |
| US-11117873-B2 | Oxazine compound, composition, and cured product | KDM5A, WDR5, SMC4 | MAPT 150/4885GAA 2983/4885JAK2 3152/4885 |
| US-11117872-B2 | Oxazine compound, composition and cured product | KDM5A, WDR5, RNF5 | MAPT 148/4885GAA 3025/4885JAK2 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.